



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: Monoclonal IgG YZ23

Catalog Number: 12047

Lot Number: 100253

Release Category: E

Provided: 400 μ L purified IgG at 200 μ g/mL, in 10mM sodium phosphate pH 7.4, 137 mM NaCl, 2.7 mM KCl.

Description: This antibody displays binary epitope reactivity directed to gp120 residues 301-311 and residues 421-433.¹

Host Site: Murine hybridoma: Mouse B cells fused with NS1 myeloma cell line.

Titer: Total protein is 200 μ g/mL by bicinchonic acid protein assay.

Special Characteristics: Immunogen: gp120MN derivatized with electrophilic phosphate diester groups.²

IgG neutralizes subtype C HIV strain 97ZA009 (primary isolate) with an IC₅₀ value of 8.2 μ g/mL using pooled human peripheral blood mononuclear cells (PBMC). Endotoxin concentration in stock IgG solution is 0.14 EU/mL. The endotoxin concentration will be 0.006 EU/mL at final concentration in the neutralization assay equivalent to the IC₅₀ (8.2 μ g/mL); Binds electrophilic 416-433 peptide detectably at 50 μ g/mL¹.

This antibody preparation does not neutralize pseudovirion infection of the TZm-bl cell line. It neutralizes infection of PHA-activated human PBMCs by genetically diverse primary strains [belonging to subtypes A, B and C].¹

Neutralization assays are conducted as in ref 3. Briefly, human PBMCs are pooled from 4 non-HIV-infected donors and activated with 5 μ g/mL phytohemagglutinin for 3 days. Virus stock is diluted in "RPMI medium" (RPMI 1640, antibiotics, 5% IL-2, 20% FBS). A primary isolate (for example, CCR5-dependent subtype C 97ZA009, 100 TCID₅₀ per well) is incubated for 1 hour with antibody diluted 1:2 in RPMI medium, and diluted further with 1:1 RPMI:PBS mixture. The mixture is then added into the wells containing 250,000 PBMCs in RPMI medium, and incubated for 3 days. Cells are washed and intracellular p24 is measured by ELISA on day 4. Titer assay variability of neutralization was determined in

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

is measured by ELISA on day 4. Inter-assay variability or neutralization was determined in 26 repeat assays using the subtype C virus ZA009. Neutralization was detectable in 26 out of 26 assays. The IC50 values varied from 0.5-59 µg/mL.

Recommended Storage: -80°C

Contributor: Drs. Sudhir Paul and Stephanie Planque.

Isotype: IgG2a,kappa

References:

1. Nishiyama Y, Planque S, Mitsuda Y, Nitti G, Taguchi H, Jin L, Symersky J, Boivin S, Sienczyk M, Salas M, Hanson CV, Paul S. Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity. *J Biol Chem.* 2009 Oct 30; **284**(44):30627-42. [Abstract](#)
2. Paul S, Planque S, Zhou YX, Taguchi H, Bhatia G, Karle S, Hanson C, Nishiyama Y. Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. *J Biol Chem.* 2003 May 30; **278**(22):20429-35. [Abstract](#)
3. Karle S, Planque S, Nishiyama Y, Taguchi H, Zhou YX, Salas M, Lake D, Thiagarajan P, Arnett F, Hanson CV, Paul S. Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library. *AIDS.* 2004 Jan 23; **18**(2):329-31. [Abstract](#)
4. Nishiyama Y, Karle S, Mitsuda Y, Taguchi H, Planque S, Salas M, Hanson C, Paul S. Towards irreversible HIV inactivation: stable gp120 binding by nucleophilic antibodies. *J Mol Recognit.* 2006 Sep-Oct; **19**(5):423-31. [Abstract](#)

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Monoclonal IgG YZ23 (Cat #12047) from Drs. Sudhir Paul and Stephanie Planque." Also include the references cited above in any publications.

Limited to 1 aliquot per lab.

Reagent must not be used or incorporated for commercial purposes.

Last Updated August 27, 2014

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.